KEYMED BIO-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Apr 24 04:37 ET
KEYMED BIO-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Apr 24 04:35 ET
KEYMED BIO-B: FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
Apr 24 04:34 ET
KEYMED BIO-B: NOTICE OF ANNUAL GENERAL MEETING
Apr 24 04:33 ET
KEYMED BIO-B: (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (4) RE-APPOINTMENT OF AUDITOR; AND (5) NOTICE OF ANNUAL GENERAL MEETING
Apr 24 04:32 ET
KEYMED BIO-B: 2023 ANNUAL REPORT
Apr 24 04:30 ET
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA ON CMG901 (AZD0901)
Apr 11 20:15 ET
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Apr 8 04:52 ET
KEYMED BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
Mar 26 09:39 ET
KEYMED BIO-B: DATE OF BOARD MEETING
Mar 14 04:31 ET
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Mar 6 03:38 ET
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Feb 6 03:39 ET
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE 2022 RESTRICTED SHARE UNIT SCHEME
Jan 22 05:15 ET
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Jan 2 05:52 ET
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ACHIEVED PRIMARY ENDPOINTS
Dec 26, 2023 19:15 ET
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADULTS ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Dec 6, 2023 23:21 ET
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Dec 4, 2023 03:45 ET
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT THE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OF CMG901 AT THE ASCO PLENARY SERIES BY WAY OF ORAL PRESENTATION
Nov 7, 2023 19:15 ET
KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Nov 6, 2023 03:32 ET
KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT CM310 PHASE III CLINICAL TRIAL TOPLINE DATA ACCEPTED FOR POSTER SESSION AT THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS 2023
Oct 11, 2023 04:30 ET
No Data
No Data